Literature DB >> 28608925

Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy.

Francesca Caparrotti1, Shao Hui Huang1, Lin Lu2, Scott V Bratman1, Jolie Ringash1, Andrew Bayley1, John Cho1, Meredith Giuliani1, John Kim1, John Waldron1,3, Aaron Hansen4, Li Tong1, Wei Xu2, Brian O'Sullivan1,3, Robert Wood5, David Goldstein3, Andrew Hope1.   

Abstract

BACKGROUND: Osteoradionecrosis (ORN) of the mandible is a late toxicity affecting patients treated with radiotherapy for head and neck malignancies. To the authors' knowledge, ORN has no standardized grading system and its reporting is based on retrospective findings in heterogeneous patient populations. The rate of ORN in the era of intensity-modulated radiotherapy (IMRT) still is unknown.
METHODS: The authors report the incidence of ORN from prospectively collected data regarding 1196 patients who were diagnosed with squamous cell carcinoma of the oropharynx and treated with curative-intent IMRT, with or without concomitant systemic treatment, from January 2005 to December 2014. Each case of ORN was graded according to its severity. Clinical and dosimetric comparisons were performed between patients with ORN and a matched control cohort of patients without ORN.
RESULTS: The actuarial rate of ORN of the mandible was 3% at 1 year, 5% at 3 years, and 7% at 5 years. On multivariable analysis, smoking (hazard ratio, 1.9; 95% confidence interval, 1.07-3.4 [P = .03]) and T classification (hazard ratio, 1.78; 95% confidence interval, 1.02-3.1 [P = .041]) were found to be statistically significant risk factors. The presence of cardiovascular comorbidities, use of bisphosphonates, and pre-IMRT dental extractions were found to be different between the matched cohorts. The mandibular volume receiving 50 grays (Gy) (in cm3 ) and the volume receiving 60 Gy (in cm3 ) were found to be associated with ORN on multivariable analysis in the matched cohort patients receiving an IMRT regimen of 2 Gy per fraction.
CONCLUSIONS: ORN is relatively uncommon among patients with oropharyngeal carcinoma who are treated with IMRT, but continues to occur beyond 5 years after treatment. Modifiable risk factors that are associated with higher rates of ORN include smoking and the use of bisphosphonates. Minimizing the volumes of the mandible receiving >50 Gy or > 60 Gy also may have an effect on the ORN rate. Cancer 2017;123:3691-3700.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  intensity-modulated radiotherapy (IMRT); late toxicity; mandible; oropharyngeal carcinoma; osteoradionecrosis

Mesh:

Substances:

Year:  2017        PMID: 28608925     DOI: 10.1002/cncr.30803

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Revisiting the dose constraints for head and neck OARs in the current era of IMRT.

Authors:  N Patrik Brodin; Wolfgang A Tomé
Journal:  Oral Oncol       Date:  2018-09-08       Impact factor: 5.337

2.  Register-based observational studies - who will endorse that maternal smoking lowers the odds for developing hay fever and eczema?

Authors:  Asbjørn Jokstad
Journal:  Clin Exp Dent Res       Date:  2017-12-22

Review 3.  To extract or not extract teeth prior to head and neck radiotherapy? A systematic review and meta-analysis.

Authors:  Ana Gabriela Costa Normando; Maria Eduarda Pérez-de-Oliveira; Eliete Neves Silva Guerra; Márcio Ajudarte Lopes; André Caroli Rocha; Thaís Bianca Brandão; Ana Carolina Prado-Ribeiro; Luiz Alcino Monteiro Gueiros; Joel B Epstein; César Augusto Migliorati; Alan Roger Santos-Silva
Journal:  Support Care Cancer       Date:  2022-06-17       Impact factor: 3.603

4.  Orthognathic surgery in patients with systemic diseases.

Authors:  Katrien Brijs; Hilde Peeters; Constantinus Politis
Journal:  Oral Maxillofac Surg       Date:  2022-03-28

5.  Outcomes after definitive surgery for mandibular osteoradionecrosis.

Authors:  Kevin J Contrera; Steven B Chinn; Randal S Weber; Dianna Roberts; Jeffery N Myers; Stephen Y Lai; Carol M Lewis; Amy C Hessel; Ann M Gillenwater; Collin F Mulcahy; Peirong Yu; Matthew M Hanasono; Clifton D Fuller; Mark S Chambers; Mark E Zafereo
Journal:  Head Neck       Date:  2022-03-03       Impact factor: 3.821

Review 6.  Osteoradionecrosis of the Maxilla: Conservative Management and Reconstructive Considerations.

Authors:  Tom Shokri; Weitao Wang; Aurora Vincent; Jason E Cohn; Sameep Kadakia; Yadranko Ducic
Journal:  Semin Plast Surg       Date:  2020-05-06       Impact factor: 2.314

7.  Temporal Bone Osteoradionecrosis: An 18-year, Single-Institution Experience.

Authors:  Benjamin D Lovin; Mike Hernandez; Hunter Elms; Jonathan S Choi; Nathan R Lindquist; Amy C Moreno; Marc-Elie Nader; Paul W Gidley
Journal:  Laryngoscope       Date:  2021-07-20       Impact factor: 2.970

8.  Retrospective study of survival in human papillomavirus-negative oropharyngeal squamous cell carcinoma treated with primary surgery and associated prognostic factors.

Authors:  Yuan Yuan; Lin Wang; Qing-Xiang Li; Jian-Yun Zhang; Zhi-Xiu Xu; Chuan-Bin Guo
Journal:  Onco Targets Ther       Date:  2018-04-27       Impact factor: 4.147

9.  Osteoradionecrosis of the jaw in a patient with lymphoma treated with rituximab and concomitant involved field radiation therapy.

Authors:  Jesus D Gonzalez-Lugo; Rafi Kabarriti; Ioannis Mantzaris
Journal:  Adv Radiat Oncol       Date:  2018-06-04

10.  Wound monitoring of pH and oxygen in patients after radiation therapy.

Authors:  Steffen Auerswald; Stephan Schreml; Robert Meier; Alexandra Blancke Soares; Maximilian Niyazi; Sebastian Marschner; Claus Belka; Martin Canis; Frank Haubner
Journal:  Radiat Oncol       Date:  2019-11-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.